annb0t
Top 20
Mesoblast Limited (NASDAQ: MESO) announced top-line long-term survival results for remestemcel-L from its Phase 3 trial (GVHD-001) in children with steroid-refractory acute graft-versus-host disease (SR-aGVHD). The results showed durable survival through 4 years of follow-up. These new long-term survival data are a key component of the company's BLA resubmission to the FDA for remestemcel-L in treating children with SR-aGVHD. A four-year observational cohort survival study was performed on 51 ev...
>>> Read more: Mesoblast Lead Product Shows Durable Long-Term Survival At Four Years In Kids With Graft Versus Host Disease
>>> Read more: Mesoblast Lead Product Shows Durable Long-Term Survival At Four Years In Kids With Graft Versus Host Disease
